OBiO Technology to Present Data on OVersatile™ Platform for Process Development of Herpes Simplex Virus and Vaccinia Virus Products at the 25th ASGCT Annual Meeting
May 9, 2022
SHANGHAI, May 9, 2022 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', SSE:688238.SH), a gene and cell therapy-focused biotechnology company, serving as a contract research organization for vectorology and functional genomics studies, and providing contract development and manufacturing services of IND-enabling CMC, clinical and commercial manufacturing, today announced that research on novel manufacturing technologies via its OVersatile™ platform will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual meeting on May 16-19, 2022 in Washington, D.C.

Empowered by robust manufacturing technologies and a comprehensive quality control system, the OVersatile™ platform enables flexible and high-quality process development and manufacturing solutions for a variety of gene and cell therapy products. Through research and development on novel manufacturing technologies with enhanced manufacturability, developability, and efficiency, the platform facilitates a high-titer, large-scale production capability and provides versatile development possibilities for various demands. The presentations highlight research on the upstream process development of herpes simplex virus and vaccinia virus products with the application of novel manufacturing technologies.

Details of the poster presentations:

Title: Development of Scalable Vaccinia Virus-Based Vector Production Process Using Dissolvable Porous Microcarriers
Session Date/Time: Monday, May 16, 2022, 5:30 p.m. - 6:30 p.m. EST
Session Title: Vector Product Engineering, Development or Manufacturing I
Abstract Number: 414
Poster Board Number: M-295

Title: High-Titer Herpes Simplex Virus Type 1-Based Vector Manufacturing Using Univercells Technologies' Production System
Session Date/Time: Tuesday, May 17, 2022 5:30 p.m. - 6:30 p.m. EST
Session Title: Vector Product Engineering, Development or Manufacturing II
Abstract Number: 768
Poster Board Number: Tu-273

About OBiO

OBiO Technology (Shanghai) Corp., Ltd. (OBiO, SSE:688238.SH) is a gene and cell therapy-focused biotechnology company founded in 2013. In China for global customers, we offer holistic research, development, and manufacturing solutions for vectorology studies, functional genomics, process and analytical development, IND-enabling CMC, clinical and commercial manufacturing. With "enable gene therapy for better lives" as our mission, we are committed to providing high-quality service to global customers, advancing your product from bench to clinic, and bringing benefit to populations around the world. For more information about OBiO, visit

Related Link

First Name*
Last Name*
Phone Number*
I'm interested in…
Questions or Comments
Security Code*
By submitting this form I agree that OBiO may process my data in the manner described in OBiO’s Privacy Policy
We won’t share your information.
Upcoming Events
© 2022 OBiO Technology (Shanghai) Corp., Ltd. All Rights Reserved